Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07258511 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

Study acronym: TRIlogy-4
StatusRecruiting
PhasePhase 3
Started2026-02-04
View on ClinicalTrials.gov ↗
The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.

Amendment history 8 changes detected by DataLookout

2026-08-29
Trial sites expanded: 124 → 144 locations
2026-08-01
Trial sites expanded: 109 → 124 locations
2026-07-17
Primary endpoint(s) modified
WasOverall Response Rate (ORR), Progression-Free Survival (PFS)
NowOverall Response, Progression-Free Survival (PFS)
2026-07-17
Trial sites expanded: 103 → 109 locations
2026-07-07
Trial sites expanded: 65 → 103 locations
2026-06-06
Trial sites expanded: 43 → 65 locations
2026-05-09
Trial sites expanded: 39 → 43 locations
2026-04-14
Trial sites expanded: 33 → 39 locations
Trial Details
NCT Number NCT07258511
Lead Sponsor Janssen Research & Development, LLC
Conditions Multiple Myeloma
Enrollment 400 participants
Start Date 2026-02-04
Primary Completion 2028-12-12 (estimated)
Study Completion 2031-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-28